

Track record – Diseases – Cardiovascular disease

Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: a retrospective analysis based on 6,725 VTE patients. Böttger B, Wehling M, Bauersachs RM, Amann S, Schuchert A, Reinhold C, Kümpers P, Wilke T. *Thromb Res.* 2014 Nov;134(5):1014-9. doi: 10.1016/j.thromres.2014.09.003. Epub 2014 Sep 9.

Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. *PLoS One.* 2014 Nov 5;9(11):e111247. doi: 10.1371/journal.pone.0111247. eCollection 2014.

Direct costs of hypertensive patients admitted to hospital in Vietnam- a bottom-up micro-costing analysis. Nguyen TP, Nguyen TB, Nguyen TT, Vinh Hac V, Le HH, Schuiling-Veninga C, Postma MJ. *BMC Health Serv Res.* 2014 Oct 28;14:514. doi: 10.1186/s12913-014-0514-4.

Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. Stevanović J, Pompen M, Le HH, Rozenbaum MH, Tieleman RG, Postma MJ. *PLoS One.* 2014 Aug 5;9(8):e103974. doi: 10.1371/journal.pone.0103974. eCollection 2014.

Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. Vegter S, Oosterhof P, van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ. *J Manag Care Pharm.* 2014 Jul;20(7):722-32.

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Bergmeijer TO, Janssen PW, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS, Asselbergs FW, van 't Hof AW, Dewilde WJ, Spanó F, Herrman JP, Kelder JC, Postma MJ, de Boer A, Deneer VH, ten Berg JM. *Am Heart J.* 2014 Jul;168(1):16-22.e1. doi: 10.1016/j.ahj.2014.03.006. Epub 2014 Mar 21.

Networks for improving care in patients with acute coronary syndrome: A framework. Radke PW, Halvorsen S, Jukema JW, Kolh P, Annemans L, Postma MJ, Ardissino D, Kristensen SD, Bassand JP, Collet JP, Morais J, Tuñón J, Halcox J. *Acute Card Care.* 2014 Jun;16(2):41-8. doi: 10.3109/17482941.2014.881502. Epub 2014 Mar 21.

Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. Stevanović J, O'Prinsen AC, Verheggen BG, Schuiling-Veninga N, Postma MJ, Pechlivanoglou P. *Clin Ther.* 2014 Mar 1;36(3):368-84.e5. doi: 10.1016/j.clinthera.2014.01.008. Epub 2014 Feb 15.

Assessing Uncertainties Surrounding Combined Endpoints for Use in Economic Models. Heeg B, van Hout B. *Medical Decision Making* 2014 Apr;34(3):300-10.

Preferences Regarding The Attributes Of Oral Anticoagulants In Patients With Atrial Fibrillation Results Of A Discrete Choice Experiment. Böttger B, Thate-Waschke IM, Bauersachs R, Kohlmann T, Wilke T. *Value in Health.* 2014;17(7):A495.

Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: A retrospective analysis based on 6,725 VTE patients. Böttger B, Wehling M, Bauersachs RM, Amann S, Schuchert A, Reinhold C, Kümpers P, Wilke T. *Thromb Res.* 2014;134(5):1014–1019.

Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, Krabbe B. *J Thromb Thrombolysis.* 2014;Epub ahead of print

The quality of oral anticoagulation in general practice in patients with atrial fibrillation. Müller S, Pfannkuche M, Breithardt G, Bauersachs R, Maywald U, Kohlmann T, Wilke T. *Eur J Intern Med.* 2014;25(3):247-254.

Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function. Böttger B, Wehling M, Bauersachs RM, Amann S, Wilke T. *J Public Health.* 2014;22(2):89-99.

Treatment of Patients with Atrial Fibrillation: Analysis of Incidence and Clinical Outcomes Based on a German Claims Based Data Set. Wilke T, Groth A, Müller S, Hastedt C, Fuchs A, Maywald U. *Interruption/Bridging of VKA Value in Health.* 2013;16(7):A517.

Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function. Böttger B, Wehling M, Bauersachs RM, Amann S, Wilke T. *Value in Health*. 2013;16(7):A538.

Incidence and prevalence of atrial fibrillation: An analysis based on 8.3 million patients. Wilke T, Groth A, Müller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Bauersachs R, Breithardt G. *Europace*. 2013;15(4):486-93.

Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. *Drugs*. 2012 Dec 24;72(18):2365-73. doi: 10.2165/11638240-000000000-00000. Review.

A systematic review on the application of cardiovascular risk prediction models in pharmacoconomics, with a focus on primary prevention. Stevanovic J, Postma MJ, Pechlivanoglou P. *Eur J Prev Cardiol*. 2012 Aug;19(2 Suppl):42-53. Review.

Economic evaluation of dabigatran etexilate for the primary prevention of venous thromboembolic events following major orthopedic surgery in the Netherlands. Postma MJ, Kappelhoff BS, van Hulst M, Brouwers JR. *J Med Econ*. 2012;15(5):878-86. doi: 10.3111/13696998.2012.691144. Epub 2012 Jun 7.

Sodium intake, ACE inhibition, and progression to ESRD. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. *J Am Soc Nephrol*. 2012 Jan;23(1):165-73. doi: 10.1681/ASN.2011040430. Epub 2011 Dec 1.

Prevalence and Incidence of Atrial Fibrillation: An Analysis Based on 8.3 Million Patients. Wilke T, Groth A, Müller S, Verheyen F, Linder R, Pfannkuche M, Maywald U, Bauersachs R, Breithardt G. *Value in Health*. 2012;15(4):A115–A116.

The influence of disease-specific symptoms on the health-related quality of life in patients with atrial fibrillation. Wilke T, Müller S, Bauersachs R, Breithardt G. 2012;15(7):A379.

The quality of anticoagulation therapy in patients with atrial fibrillation. Wilke T, Müller S. *Value in Health*. 2012;15(4):A128.

Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. *Am J Manag Care*. 2011 Sep;17(9):609-16.

Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ, Wilschut JC. *J Infect Dis*. 2011 Aug 1;204(3):377-84. doi: 10.1093/infdis/jir281.

Hospital-specific calculation of heparin-induced thrombocytopenia costs: a review. Wilke T, Greinacher A. *J Lab Med* 2011;35(1); S:35-43.

Do Atrial Fibrillation (AF) Patients Get Oral Anticoagulation (OAC) as Guidelines Recom-Mend? An Analysis of German Health Insurance Claims Data. Wilke T, Mueller S, Groth A, Verheyen F, Linder R, Pfannkuche M, Breithardt G, Bauersachs R, Maywald U. *Value in Health*. 2011;14(7):A388.

Ticagrelor for the Treatment of Acute Coronary Syndromes (ACS): A Dutch Analysis Based on the Plato Trial. Thurston S, Heeg B, Hofsté C. *PCV87 Value in Health* 01/2011; 14(7)

Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis. Boersma C, Broere A, Postma MJ. *Value Health*. 2010 Sep-Oct;13(6):853-6. doi: 10.1111/j.1524-4733.2010.00736.x.

Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands. Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ; Prevention of Renal and Vascular End Stage Disease Study Group. *Clin Ther*. 2010 Jun;32(6):1103-21. doi: 10.1016/j.clinthera.2010.06.013.

Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data. Boersma C, Voors AA, Visser ST, de Jong-van den Berg LT, Postma MJ. *Am J Cardiovasc Drugs*. 2010;10(1):49-54. doi: 10.2165/11319570-000000000-00000.

Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. Thurston S, Heeg B, de Charro F, van Hout B. *Current Medical Research and Opinion* 03/2010; 26(3):641-51.

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.

Logman F, Heeg B, Herlitz J, van Hout B. *Applied Health Economics and Health Policy* 01/2010; 8(4):251-65.

Non-adherence in Outpatient Thromboprophylaxis after Major Orthopedic Surgery: a systematic Review. Wilke T, Müller S. *Pharmacoeconomics and Outcomes Research*. 2010;(6):691-700

Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Vegter S, Perna A, Hiddema W, Ruggerenti P, Remuzzi G, Navis G, Postma MJ. *Pharmacogenetics and Genomics*. 2009 Sep;19(9):695-703. doi: 10.1097/FPC.0b013e3283307ca0.

The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. Journal of Thrombosis and Hemostasis. Wilke T, Tesch S, Scholz A, Kohlmann T, Greinacher A 2009;7(5):766–773.

Patient preferences for an oral anticoagulant after major orthopedic surgery: results of a German survey. Wilke T. *The Patient*. 2009;2(1):39-49.

Non-Adherence in outpatient prophylaxis after major orthopedic surgery. Wilke T. *Value in Health*. 2009;12(7):A221.

Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. Boersma C, Postma MJ, Visser ST, Atthobari J, de Jong PE, de Jong-van den Berg LT, Gansevoort RT; PREVENT Study Group. *Br J Clin Pharmacol*. 2008 May;65(5):723-32. doi: 10.1111/j.1365-2125.2008.03097.x. Epub 2008 Jan 30.

Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Ivanovic N, Beinema M, Brouwers JR, Naunton M, Postma MJ. *Expert Rev Pharmacoeconomics Outcomes Res*. 2007 Feb;7(1):49-58. doi: 10.1586/14737167.7.1.49.

Oral anticoagulation after major hip and knee replacement surgeries. Wilke T. *Value in Health*. 2008;11(6):A390.

An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. Boersma C, Carides GW, Atthobari J, Voors AA, Postma MJ. *Clin Ther*. 2007 May;29(5):963-71.

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVENT) study and the prevention of renal and vascular endstage disease intervention trial (PREVENT IT). Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ; PREVENT IT Study Group. *Clin Ther*. 2006 Mar;28(3):432-44.

Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. Heeg B, Peters R, Botteman M, van Hout B. *Pharmacoeconomics* 02/2007; 25(9):769-82.

Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. Heeg B, Damen D, van Hout B. *Pharmacoeconomics* 02/2007; 25(12):1063-82.

Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. Klok RM, Boersma C, Oosterhuis I, Visser ST, de Jong-van den Berg LT, Postma MJ. *Aliment Pharmacol Ther*. 2006 Jun 1;23(11):1595-600.

[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark]. Heeg B, van Gestel A, van Hout B, Olsen J, Haghfelt T. *Ugeskrift for læger* 09/2006; 168(35):2911-5

Cost-effectiveness of screening for proteinuria. Gansevoort RT, de Jong PE, Postma MJ. *JAMA*. 2004 Mar 24;291(12):1442-3; author reply 1443. No abstract available.